High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS.
Journal
Neurology(R) neuroimmunology & neuroinflammation
ISSN: 2332-7812
Titre abrégé: Neurol Neuroimmunol Neuroinflamm
Pays: United States
ID NLM: 101636388
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
11
01
2019
accepted:
29
04
2019
entrez:
14
9
2019
pubmed:
14
9
2019
medline:
25
9
2020
Statut:
epublish
Résumé
To evaluate neurofilament light chain (NfL) levels in serum and CSF of patients with aggressive MS pre- and post-treatment with immunoablation followed by autologous hematopoietic stem cell transplantation (IAHSCT) and examine associations with clinical and MRI outcomes. Paired serum and CSF in addition to MRI and clinical measures were collected on 23 patients with MS at baseline and 1 and 3 years post-IAHSCT. An additional 33 sera and CSF pairs were taken from noninflammatory neurologic controls. NfL levels were quantitated using the Simoa platform (Quanterix). Baseline MS NfL levels were significantly elevated relative to controls in serum ( These data substantiate that serum and CSF NfL levels reflect disease severity and treatment response in patients with MS and may therefore be a useful biomarker. Baseline serum levels associated with markers of pretreatment disease severity and post-treatment outcomes. This study provides Class II evidence that for patients with aggressive MS, serum NfL levels are associated with disease severity.
Identifiants
pubmed: 31516913
doi: 10.1212/NXI.0000000000000598
pii: NEURIMMINFL2019019885
pmc: PMC6715458
doi:
Substances chimiques
Biomarkers
0
Neurofilament Proteins
0
neurofilament protein L
0
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e598Commentaires et corrections
Type : CommentIn
Références
Neuroimage. 2002 Sep;17(1):479-89
pubmed: 12482100
Arch Clin Neuropsychol. 2006 Jan;21(1):53-76
pubmed: 16290063
Neurol Sci. 2008 Sep;29 Suppl 2:S250-2
pubmed: 18690508
Brain. 1991 Apr;114 ( Pt 2):1045-56
pubmed: 2043940
Nat Biotechnol. 2010 Jun;28(6):595-9
pubmed: 20495550
Ann Neurol. 2010 Dec;68(6):806-15
pubmed: 21194151
J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1192-8
pubmed: 23744892
Neuroimage Clin. 2013 Oct 29;4:10-7
pubmed: 24266007
Mult Scler. 2015 May;21(6):675-6
pubmed: 25623248
Nat Rev Neurol. 2015 Jun;11(6):327-38
pubmed: 26009002
Nat Rev Neurol. 2015 Aug;11(8):471-82
pubmed: 26149978
Clin Neuroradiol. 2015 Oct;25 Suppl 2:157-65
pubmed: 26198879
Clin Chem Lab Med. 2016 Oct 1;54(10):1655-61
pubmed: 27071153
Lancet. 2016 Aug 6;388(10044):576-85
pubmed: 27291994
J Neurochem. 2017 Apr;141(2):296-304
pubmed: 27787906
Neurology. 2017 Feb 28;88(9):826-831
pubmed: 28148632
Ann Neurol. 2017 Jun;81(6):857-870
pubmed: 28512753
Mult Scler. 2018 Jul;24(8):1046-1054
pubmed: 28627962
Neurology. 2017 Nov 28;89(22):2230-2237
pubmed: 29079686
Neurol Neuroimmunol Neuroinflamm. 2017 Nov 28;5(1):e422
pubmed: 29209636
Brain. 2018 Aug 1;141(8):2382-2391
pubmed: 29860296
Mult Scler. 2018 Sep 25;:1352458518802544
pubmed: 30251913
Ann Clin Transl Neurol. 2018 Oct 16;5(12):1478-1491
pubmed: 30564615
Qual Life Res. 1995 Jun;4(3):187-206
pubmed: 7613530
J Neurosci. 1997 Jan 1;17(1):171-80
pubmed: 8987746